MedTrace Logo

An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

NCT02845674 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2021-11-19

Study results available
· View outcomes & findings →

Summary

This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)

Conditions

  • Keratoconjunctivitis Sicca

Interventions

DRUG

OTX-101 0.09%

0.09% cyclosporine nanomicellar solution

Sponsors & Collaborators

  • Sun Pharmaceutical Industries Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-29
Primary Completion
2017-08-15
Completion
2017-08-15
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02845674 on ClinicalTrials.gov